Please ensure Javascript is enabled for purposes of website accessibility

What Happened in the Stock Market Today

By Jim Crumly – Aug 26, 2019 at 4:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Bristol-Myers Squibb and Celgene made a deal to sell a blockbuster drug to Amgen, and Disney and Target are forming a retail collaboration.

Investors trying to divine the state of the trade war with China were heartened by optimistic comments from President Trump on Monday, sending major benchmarks higher. The Dow Jones Industrial Average (^DJI 0.45%) and the S&P 500 (^GSPC -0.03%) both gained about 1%. The communication services and technology sectors led the buying.

Today's stock market

Index Percentage Change Point Change
Dow 1.05% 269.93
S&P 500 1.10% 31.27

Data source: Yahoo! Finance.

As for individual stocks, Bristol-Myers Squibb (BMY 0.13%) and Celgene (CELG) announced plans to sell a blockbuster drug to Amgen (AMGN 0.12%), and Target (TGT -0.02%) and Disney (DIS -0.01%) are forming a retail collaboration.

Upward bar graph.

Image source: Getty Images.

Bristol-Myers and Celgene deal a drug to Amgen

Bristol-Myers Squibb moved a step closer to completing its planned acquisition of Celgene after the companies announced an agreement to sell anti-inflammatory drug Otezla to Amgen for $13.4 billion. Investors thought the deal was a winner for everybody, sending Bristol shares up 3.3%, Celgene up 3.2%, and Amgen up 3.2%.

The U.S. Federal Trade Commission had expressed concern about the strong position that the proposed merger would create in anti-inflammatory drugs, and when Bristol-Myers announced in June that it was looking for a buyer for Celgene's fast-growing drug in order to expedite approval of the deal, its stock plummeted. Investors may have been concerned that the companies wouldn't be able to get a good price for Otezla, but today's news seemed to satisfy them. With European approval of the merger already received last month, any doubt about a successful merger completion seems to be removed.

Amgen is rich with cash and has been expected to go on a buying spree. Otezla fits with a core growth area of the company and is projected to have $1.9 billion in sales this year, with low-double-digit growth on average over the next five years.

Target and Disney team up for merchandise sales

Disney and Target announced a retail collaboration to open Disney stores within Target locations and to open a Target store at an entrance to the Walt Disney World Resort. Shares of Target rose 1.2% and those of Disney gained 2.2%.

The companies will launch "shop-in-shop" Disney stores averaging 750 square feet inside Target locations, starting with 25 U.S. spots opening Oct. 4, with 40 additional stores coming on line by October 2020. The embedded stores will sell an assortment of more than 450 items of Disney merchandise, including more than 100 products that are currently only available at Disney retail locations. The merchandise will also be available on Target's web site and mobile app.

Disney expects growth from its merchandising business, with items from Frozen 2 and Star Wars: The Rise of Skywalker boosting results this holiday season, and the leveraging of newly acquired Fox assets helping longer-term. Meanwhile, Target is on a roll, having created a successful formula for fulfillment of digital orders and giving shoppers more reasons to visit its physical stores.

Jim Crumly owns shares of Target and Walt Disney. The Motley Fool owns shares of and recommends Celgene and Walt Disney. The Motley Fool has the following options: long January 2021 $60 calls on Walt Disney and short October 2019 $125 calls on Walt Disney. The Motley Fool recommends Amgen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.